Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Multiple Sclerosis

  Free Subscription


Articles published in Can J Neurol Sci

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    June 2025
  1. FREEDMAN MS, Clift F, Devonshire V, Emond F, et al
    First-line use of higher-efficacy disease-modifying therapies in multiple sclerosis: Canadian consensus recommendations.
    Can J Neurol Sci. 2025 Jun 9:1-28. doi: 10.1017/cjn.2025.10342.
    PubMed    


    May 2025
  2. FREEDMAN DE, Sundaram ANE, Oh J, Feinstein A, et al
    How does time of testing influence cognitive performance in multiple sclerosis?
    Can J Neurol Sci. 2025 May 19:1-7. doi: 10.1017/cjn.2025.10125.
    PubMed    


    March 2025
  3. FIFIELD KE, Fudge NJ, Arsenault ST, Anthony S, et al
    An overview of multiple sclerosis care in rural and urban Newfoundland and Labrador.
    Can J Neurol Sci. 2025 Mar 12:1-25. doi: 10.1017/cjn.2025.
    PubMed    


  4. NATHOO N, Clark WI, Robinson R, Jarvis S, et al
    Indigenous Peoples Living with Multiple Sclerosis in Canada.
    Can J Neurol Sci. 2025 Mar 4:1-14. doi: 10.1017/cjn.2025.
    PubMed    


  5. GUILLEMETTE A, Roberge D, Menard C, Bahary JP, et al
    Outcomes of CyberKnife Radiosurgery for Trigeminal Neuralgia in Patients with Multiple Sclerosis.
    Can J Neurol Sci. 2025 Mar 3:1-22. doi: 10.1017/cjn.2025.
    PubMed    


    November 2024
  6. SA'DI Q, Alsmadi S, Shtaiyat W, Qasaimeh M, et al
    FLVCR1 Gene Mutation in a Patient with an Atypical Multiple Sclerosis-Like Presentation.
    Can J Neurol Sci. 2024 Nov 27:1-12. doi: 10.1017/cjn.2024.
    PubMed    


  7. GONCUOGLU C, Acar-Ozen P, Kasikci M, Tuncer A, et al
    Pharmacist-implemented self-management module in multiple sclerosis patients: A randomized controlled trial.
    Can J Neurol Sci. 2024 Nov 13:1-27. doi: 10.1017/cjn.2024.
    PubMed    


    October 2024
  8. MCCOMBE JA, Smyth P, Kate M, So H, et al
    Healthcare Cost of Multiple Sclerosis and in Relation to Disability Level in Alberta.
    Can J Neurol Sci. 2024 Oct 2:1-12. doi: 10.1017/cjn.2024.
    PubMed     Abstract available


    May 2024
  9. OH J, Bhan V, Traboulsee A, Morrow SA, et al
    Health Canada drug approval process: a barrier to personalized care in multiple sclerosis.
    Can J Neurol Sci. 2024 May 23:1-12. doi: 10.1017/cjn.2024.
    PubMed    


    April 2024
  10. BALCOM EF, McCombe JA, Kate M, Vu K, et al
    Geographical variation in medication and health resource use in multiple sclerosis.
    Can J Neurol Sci. 2024 Apr 11:1-21. doi: 10.1017/cjn.2024.
    PubMed    


    February 2024
  11. NOBILE S, Beauchemin P
    Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort.
    Can J Neurol Sci. 2024 Feb 12:1-21. doi: 10.1017/cjn.2024.
    PubMed    


    November 2023
  12. HANDZIC A, Margolin E
    Myelin Oligodendrocyte Glycoprotein-related isolated internuclear ophthalmoplegia mimicking multiple sclerosis.
    Can J Neurol Sci. 2023 Nov 7:1-5. doi: 10.1017/cjn.2023.
    PubMed    


    September 2023
  13. DHAR D, Kamble N, Pal PK
    Long Latency Reflexes in Clinical Neurology: A Systematic Review.
    Can J Neurol Sci. 2023;50:751-763.
    PubMed     Abstract available


    April 2023
  14. GIACOMINI PS, Oh J, Morrow SA, Beauchemin P, et al
    Virtual management of multiple sclerosis: providing access or just phoning it in?
    Can J Neurol Sci. 2023 Apr 17:1-11. doi: 10.1017/cjn.2023.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.